Home › Companies › IRON

Pipeline (9 active programs)

Capital (as filed)

Cash

$90.0M cash and cash equivalents · Sep 30, 2026 (10-Q)

Short-term investments

$593M Sep 30, 2026

Operating cash flow

−$40.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)

As stated in coverage

$718M cash per the update of Oct 19, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

• 2026-11-05 424B5 · At-the-market program up to $190M
• 2026-10-21 424B5 · Priced offering 6.00M shares · at $75.00 · $450M gross · 5.6% below the prior close ($79.48, Oct 20, 2026)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

• 2026-10-20 UPDATE: Disc Medicine (IRON) - The Sunlight Came Through 🔒 Paid
• 2026-09-28 Disc Medicine (IRON) — Scientific Deep Dive for Bitopertin, Selcodebart, DISC-3405 and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Disc Medicine, oldest first — the full history, never a selection. How calls are scored: the track record.

1. 2026-09-28 Watch Disc Medicine (IRON) — Scientific Deep Dive for Bitopertin, Selcodebart, DISC-3405 and Pipeline Products Disc has a real mechanism and funded balance sheet, but the company's value hinges on a single sunlight-diary endpoint that failed its prespecified Phase 2 test and is powered on its best post-hoc month, with the market already pricing better-than-even odds of success.
2. 2026-10-20 Buy core UPDATE: Disc Medicine (IRON) - The Sunlight Came Through APOLLO cleared its sunlight bar (+12.2 hours vs placebo, p=0.0010) with every secondary endpoint hitting, retiring clinical risk on bitopertin; remaining risks are regulatory and commercial, not efficacy.

• Long call · opened Oct 20, 2026 at $79.48 · -0.7% vs XBI -0.7% (Nov 6, 2026)

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

• 2026-07-30 10-Q in filings ↓

  • “We expect to share additional data in the fourth quarter of 2026.”

    matched to Selcodebart · readout other · read as fourth quarter of 2026

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (25)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Oct 18, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

• Nov 5, 2026ReleasePivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints Bitopertin NDA resubmission planned by end of 2026, with an FDA dSummary on the 8-K
• Nov 5, 20268-KCurrent report: results of operations · EX-99.1Disc's Q3 10-Q is out and the numbers have changed: 45.5M shares outstanding post-offering, ~$1.17B pro forma cash, runway into 2030, and a new ATM replacing Cantor. The balance sheet is the strongest it's ever been—but dilution math and the December 17 patent clock are both worth updating before the FDA resubmission.
• Nov 5, 2026424B5Prospectus supplement (offering)Summary on the 8-K
• Nov 5, 202610-QQuarterly reportSummary on the 8-K
• Nov 4, 2026ReleaseTwo oral presentations featuring additional data from RALLY-MF Phase 2 trial of selcodebart (DISC-0974) in anemia of myelofibrosis (MF) and RESTORE-PV Phase 2 trial of DISC-3405 in polycythemia vera (
• Nov 2, 2026ReleaseWATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
• Oct 26, 2026SCHEDULE 13D/A13D amendment
• Oct 22, 20268-KCurrent report: material agreement, results of operations, other events · EX-99.1
• Oct 21, 2026ReleaseDisc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stockvia aggregator
• Oct 21, 2026424B5Prospectus supplement (offering)
• Oct 20, 2026ReleaseWATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o
• Oct 20, 2026424B5Prospectus supplement (offering)
• Oct 19, 2026ReleaseWATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o→ BD updateSummary on the 8-K
• Oct 19, 2026ReleasePositive APOLLO trial topline results demonstrated statistically significant and clinically meaningful benefit across all study endpoints Successfully met co-primary endpoints of reduction in protopor→ BD updateSummary on the 8-K
• Oct 19, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateAPOLLO delivered: bitopertin gained +12.2 hours of pain-free sunlight per month (p=0.0010) and cut phototoxic reactions by 71% (p<0.0001) — the exact endpoints the thesis said would set the company's value — while Disc simultaneously launched a $350M equity raise to fund the NDA resubmission and launch ramp.BD extracted 1 program update from this document → IRON pipeline
• Oct 18, 2026ReleaseWATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel→ BD updateSummary on the 8-K of Oct 19, 2026BD extracted 1 program update from this document → IRON pipeline
• Sep 10, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
• Jul 30, 20268-KCurrent report: results of operations · EX-99.1
• Jul 30, 202610-QQuarterly report
• Jun 30, 20268-KCurrent report: material agreement, debt / obligation
• Jun 24, 20268-KCurrent report: shareholder vote
• May 5, 20268-KCurrent report: results of operations · EX-99.1
• May 5, 202610-QQuarterly report
• Apr 28, 2026DEFA14AProxy soliciting material
• Apr 28, 2026DEF 14AProxy statement